EU approves Wayrilz (rilzabrutinib) as the first BTK inhibitor to treat immune thrombocytopenia – Sanofi
The European Commission has approved Wayrilz (rilzabrutinib), a novel, oral, reversible, Bruton’s tyrosine kinase (BTK) inhibitor, as a new treatment for immune thrombocytopenia (ITP) in adult patients who… read more.




